Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

Category Primary study
JournalEuropean Heart Journal
Year 2023
This article has no abstract
Epistemonikos ID: 78858e3486f1fdd2da8c0976c5ba20eace91aa9c
First added on: Feb 19, 2025